Feb 16, 2022 / 10:00PM GMT
Operator
Good afternoon, ladies and gentlemen, and welcome to Marker Therapeutics conference call. (Operator Instructions) As a reminder, this conference call is being recorded. It's now my pleasure to turn the call over to Mr. Tony Kim, Chief Financial Officer at Marker. Mr. Kim, please go ahead.
Anthony H. Kim - Marker Therapeutics, Inc. - CFO
Thanks, operator. Welcome, everyone, and thank you for joining us this afternoon for our clinical program and technical operations update call. With me today are Peter Hoang, our President and Chief Executive Officer; Dr. Juan Vera, our Chief Scientific and Chief Operating Officer; and Dr. Mythili Koneru, our Chief Medical Officer.
This afternoon, we issued a news release that you can find on our website at markertherapeutics.com which include the summary of initial results and the safety lead-in portion of our Phase II AML trial as well as updates on our new manufacturing process and an overview of our near-term clinical plans.
Before we begin, as a reminder, we will be making forward-looking statements
Marker Therapeutics Inc to Host Clinical Program Update Call Transcript
Feb 17, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers